Chief investigator:Stefan Neubauer
EMPA-VISION evaluated the effect of empagliflozin on heart function in patients with chronic heart failure
Phase III randomized, double-blind placebo-controlled trial with two cohorts of patients:
72 participants were randomized; 59 participants underwent the end of study assessments as COVID-19 restrictions meant participants were unable to attend face-to-face visits from 24 March 2020 onwards.
After 12 weeks of treatment there was no significant difference in the way the heart muscle used energy (measured as the PCr/ATP ratio) between the empagliflozin and placebo groups. This was the case in both heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. The results are currently being submitted for publication. You can find more information on the results here
The newly updated DTU website now includes a webpage for each of our trials.
For ongoing trials, you can find out what type of participants we are looking for and contact details if you are interested in taking part....
Launched on 1st March 2018, we expect results from this trial will be available in 2020.